AGTC A3

Actively Recruiting // Clinical Trials // Congenital Achromatopsia // Genetic mutation // Inherited Retinal Degeneration // Kimberly Stepien // Sep 30 2020

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene

  • Sponsor: Applied Genetic Technologies Corp
  • Principal Investigator: Kimberly Stepien, MD
  • Study Coordinator: Nickie Stangel

Study objective:

To evaluate the safety and efficacy of AGTC-402 administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGA3 gene.

Study design:

The study involves 12 visits the first year, and annual visits over the next 4 years. Subjects will be enrolled sequentially in to one of seven dosing groups. Subjects will either receive varying dose levels of study agent or the maximum tolerated dose.

Inclusion criteria:

  • Male or female subjects with documented mutations in both alleles of the CNGA3 gene;
  • Retinal disease consistent with a clinical diagnosis of achromatopsia;
  • At least 18 years of age for Groups 1, 2, 3, 4, and 5 and at least 6 years of age for Groups 3a, 4a and 6;
  • Able to perform tests of visual and retinal function;
  • Visual acuity in the study eye not better than 55 ETDRS letters (Snellen equivalent 20/80) based on the average of two examinations at the baseline visit;
  • Acceptable laboratory parameters;
  • For females of childbearing potential: A negative pregnancy test within 2 days before administration of study agent.

Exclusion criteria:

  • Best-corrected visual acuity difference between the two eyes of > 15 ETDRS letters (3 lines);
  • Evidence of degenerative myopia in the study eye

Contact Nickie Stangel with questions: 608-263-8783. For more information about this study: visit clinicaltrials.govĀ